The “banned overnight” myth: what actually happened to peptides in 2023

The story most patients heard was about a sudden FDA ban. The real story is slower, more procedural — and more useful.

TL;DR

• No peptide was “banned overnight.” Several were moved to FDA Category 2 through a multi-year public process.
• Category 2 status means a 503A compounding pharmacy generally cannot prepare that substance — not that the molecule was outlawed.
• A February 2026 HHS announcement proposed returning several peptides to Category 1 pending a formal FDA Federal Register notice.

What it is

The 2023 shift was a Pharmacy Compounding Advisory Committee (PCAC) review that reclassified several peptides as Category 2 substances under the FDA’s 503A bulk substances framework (FDA 503A Bulks List). Category 2 is the FDA’s holding category for substances with identified concerns. While a substance sits in Category 2, 503A compounding pharmacies generally cannot compound it for patient-specific prescriptions.

How it works

Think of the 503A bulks list as a building permit office. Substances pass through PCAC review and end up in one of three places: Category 1 (cleared to compound), Category 2 (concerns identified, on hold), or Category 3 (under review). The 2023 changes did not outlaw any molecule. They moved building permits from the “approved” file to the “on hold” file for several peptides at once — and that is the moment clinics felt the shelves go bare.

Who asks about it

People come to this topic after reading that peptides were “banned overnight” and trying to square that story with the fact that PCAC meeting agendas were public for years before. The disconnect is between procedural reality and patient experience. Both are true.

What the research says

PCAC meeting transcripts and FDA Federal Register notices show the Category 2 designations followed multi-year reviews (Federal Register, FDA). The substances affected included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II. About 9 of the 10 most-asked-about peptides in patient forums ended up in Category 2 or under review. The February 2026 HHS announcement has not yet been finalized in the Federal Register. That final notice is the moment of legal change. The announcement is not.

What to know before considering it

Patients should not infer current availability from a 2023 headline. The category list shifts. What was unavailable then may or may not be available now, and what is available now can shift again. The Federal Register notice — not a press release — is the source of truth.

The Halftime POV

The “banned overnight” framing makes for a clean podcast quote. It is also incorrect, and it sets patients up to be confused when the rules shift again. We will report the date of the Federal Register notice — not the date of the headline.

Related reading:

• BPC-157 availability in 2026: where things actually stand
• The three-category peptide access model, explained
• How to choose a quality peptide compounding pharmacy: the quality signals

FAQ

Q: Were peptides “banned overnight” in 2023? A: No. The FDA reclassified several peptides as Category 2 substances through a multi-year, public Pharmacy Compounding Advisory Committee (PCAC) process. The change was procedural and well-telegraphed, even though many patients and clinics experienced it as sudden.

Q: What is Category 2? A: Category 2 is the FDA’s holding category for substances that the agency has identified safety or evidence concerns about for use in 503A compounding. While a substance sits in Category 2, 503A pharmacies generally cannot compound it.

Q: Which peptides were affected? A: The Category 2 list has included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II, among others. Status can shift as PCAC reviews continue.

Q: Are any of them back? A: A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal FDA Federal Register notice. The notice itself is the moment of legal change, not the announcement.

Disclaimer

As of May 2026, several peptides discussed in this article — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning several of these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• FDA, 503A Bulks List
• Federal Register — FDA Agency Page

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.